From anti-parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for alzheimer's disease

Journal of Alzheimer's Disease

Volumn 30, Issue 1, 2012, Pages 1-16

  Zheng, Hailin ^a   Amit, Tamar ^b   Bar Am, Orit ^b   Fridkin, Mati ^c   Youdim, Moussa B H ^b,d   Mandel, Silvia A ^b  

^a Intra Cellular Therapies Inc   (United States)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^d Yonsei University   (South Korea)

Author keywords

AChE MAO A and B inhibitors; Alzheimer's disease; M30; multitarget chelators; site activated

Indexed keywords

2 METHYL 5 (3,4,5 TRIMETHOXYBENZAMIDO)DECAHYDROISOQUINOLINE; ACETYLCHOLINESTERASE; AMINO ACID; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CHOLINESTERASE INHIBITOR; COPPER; DEFEROXAMINE; DONEPEZIL; HLA 20; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRON; IRON CHELATING AGENT; LADOSTIGIL; METAL; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; PEPTIDE; PHYSOSTIGMINE; PROTEIN KINASE; RASAGILINE; RIVASTIGMINE; SELEGILINE; TACRINE; UNCLASSIFIED DRUG; ZINC;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANT ACTIVITY; CELL CYCLE ARREST; CHOLINESTERASE INHIBITION; DEPRESSION; DIFFUSE LEWY BODY DISEASE; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; HUMAN; IRON CHELATION; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; UPREGULATION;

EID: 84861508122     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-120013     Document Type: Review

References (95)

1. Querfurth HW, LaFerla FM (2010) Alzheimer's disease. N Engl J Med 362, 329-344.
2. Luque FA, Jaffe SL (2009) The molecular and cellular patho-genesis of dementia of the Alzheimer's type an overview. Int Rev Neurobiol 84, 151-165.
3. Geldenhuys WJ, Youdim MB, Carroll RT, Van der Schyf CJ (2011) The emergence of designed multiple ligands for neurodegenerative disorders. Prog Neurobiol 94, 347-359.
4. Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M, Melchiorre C (2008) Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 51, 347-372. (Pubitemid 351252260)
5. Morphy R (2010) Selectively nonselective kinase inhibition: Striking the right balance. J Med Chem 53, 1413-1437.
6. Hopkins AL (2008) Network pharmacology: The next paradigm in drug discovery. Nat Chem Biol 4, 682-690.
7. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH (2008) Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 22, 209-221.
8. Chow VW, Savonenko AV, Melnikova T, Kim H, Price DL, Li T, Wong PC (2010) Modeling an anti-amyloid combination therapy for Alzheimer's disease. Sci Transl Med 2, 13ra11.
9. Guglielmotto M, Giliberto L, Tamagno E, Tabaton M (2010) Oxidative stress mediates the pathogenic effect of different Alzheimer's disease risk factors. Front Aging Neurosci 2, 3.
10. Lee HP, Zhu X, Casadesus G, Castellani RJ, Nunomura A, Smith MA, Lee H-g, Perry G (2010) Antioxidant approaches for the treatment of Alzheimer's disease. Expert Rev Neurother 10, 1201-1208.
11. Drake J, Link CD, Butterfield DA (2003) Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic Caenorhabditis elegans model. Neurobiol Aging 24, 415-420. (Pubitemid 36210870)
12. Smith MA, Hirai K, Hsiao K, Pappolla MA, Harris PL, Sied-lak SL, Tabaton M, Perry G (1998) Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 70, 2212-2215. (Pubitemid 28207848)
13. Anantharaman M, Tangpong J, Keller JN, Murphy MP, Markesbery WR, Kiningham KK, St Clair DK (2006) Beta-amyloid mediated nitration of manganese superoxide dismutase: Implication for oxidative stress in a APPNLH/NLH X PS-1P264L/P264L double knock-in mouse model of Alzheimer's disease. Am J Pathol 168, 1608-1618.
14. Cheng SY, Trombetta LD (2004) The induction of amyloid precursor protein and alpha-synuclein in rat hippocampal astrocytes by diethyldithiocarbamate and copper with or without glutathione. Toxicol Lett 146, 139-149. (Pubitemid 37487828)
15. Patil S, Sheng L, Masserang A, Chan C (2006) Palmitic acid-treated astrocytes induce BACE1 upregulation and accumulation of C-terminal fragment of APP in primary cortical neurons. Neurosci Lett 406, 55-59. (Pubitemid 44278378)
16. Borghi R, Patriarca S, Traverso N, Piccini A, Storace D, Garuti A, Gabriella C, Patrizio O, Massimo T (2007) The increased activity of BACE1 correlates with oxidative stress in Alzheimer's disease. Neurobiol Aging 28, 1009-1014. (Pubitemid 46635907)
17. Tamagno E, Bardini P, Obbili A, Vitali A, Borghi R, Zaccheo D, Pronzato MA, Danni O, Smith MA, Perry G, Tabaton M (2002) Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis 10, 279-288. (Pubitemid 35217581)
18. Tamagno E, Parola M, Bardini P, Piccini A, Borghi R, Guglielmotto M, Santoro G, Davit A, Danni O, Smith MA, Perry G, Tabaton M (2005) Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. J Neurochem 92, 628-636. (Pubitemid 40189465)
19. Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, Floyd RA, Butterfield DA (1994) A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: Relevance to Alzheimer disease. Proc Natl Acad Sci USA 91, 3270-3274.
20. Yatin SM, Varadarajan S, Link CD, Butterfield DA (1999) In vitro and in vivo oxidative stress associated with Alzheimer's amyloid beta-peptide (1-42). Neurobiol Aging 20, 325-330; discussion 339-342. (Pubitemid 29525418)
21. Duce JA, Bush AI (2010) Biological metals and Alzheimer's disease: Implications for therapeutics and diagnostics. Prog Neurobiol 92, 1-18.
22. Huang X, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, Scarpa RC, Cuajungco MP, Gray DN, Lim J, Moir RD, Tanzi RE, Bush AI (1999) The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38, 7609-7616. (Pubitemid 29289332)
23. Huang X, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall JD, Hanson GR, Stokes KC, Leopold M, Multhaup G, Goldstein LE, Scarpa RC, Saunders AJ, Lim J, Moir RD, Glabe C, Bowden EF, Masters CL, Fairlie DP, Tanzi RE, Bush AI (1999) Cu (II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem 274, 37111-37116.
24. Yamamoto A, Shin RW, Hasegawa K, Naiki H, Sato H, Yoshimasu F, Kitamoto T (2002) Iron (III) induces aggregation of hyperphosphorylated tau and its reduction to iron (II) reverses the aggregation: Implications in the formation of neurofibrillary tangles of Alzheimer's disease. J Neurochem 82, 1137-1147. (Pubitemid 34966626)
25. Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gun-shin H, Leiter L, McPhee J, Sarang SS, Utsuki T, Greig NH, Lahiri DK, Tanzi RE, Bush AI, Giordano T, Gullans SR (2002) An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem 277, 45518-45528. (Pubitemid 36159162)
26. Silvestri L, Camaschella C (2008) A potential pathogenetic role of iron in Alzheimer's disease. J Cell Mol Med 12, 1548-1550.
27. Lin R, Chen X, Li W, Han Y, Liu P, Pi R (2008) Exposure to metal ions regulates mRNA levels of APP and BACE1 in PC12 cells: Blockage by curcumin. Neurosci Lett 440, 344-347.
28. Wang CY, Wang T, Zheng W, Zhao BL, Danscher G, Chen YH, Wang ZY (2010) Zinc overload enhances APP cleavage and Abeta deposition in the Alzheimer mouse brain. PLoS One 5, e15349.
29. Borchardt T, Schmidt C, Camarkis J, Cappai R, Masters CL, Beyreuther K, Multhaup G (2000) Differential effects of zinc on amyloid precursor protein (APP) processing in copper-resistant variantsofcultured Chinese hamster ovary cells. Cell Mol Biol 46, 785-795.
30. Cuajungco MP, Faget KY (2003) Zinc takes the center stage: Its paradoxical role in Alzheimer's disease. Brain Res Brain Res Rev 41, 44-56. (Pubitemid 36044593)
31. Duce JA, Tsatsanis A, Cater MA, James SA, Robb E, Wikhe K, Leong SL, Perez K, Johanssen T, Greenough MA, Cho HH, Galatis D, Moir RD, Masters CL, McLean C, Tanzi RE, Cappai R, Barnham KJ, Ciccotosto GD, Rogers JT, Bush AI (2010) Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited byzincin Alzheimer's disease. Cell 142, 857-867.
32. Fowler JS, Volkow ND, Wang GJ, Logan J, Pappas N, Shea C, MacGregor R (1997) Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neu-robiol Aging 18, 431-435. (Pubitemid 27435085)
33. van der Flier WM, Scheltens P (2005) Epidemiology and risk factors of dementia. J Neurol Neurosurg Psychiatry 76 (Suppl 5), v2-v7. (Pubitemid 41719232)
34. Saura J, Luque JM, Cesura AM, Da Prada M, Chan-Palay V, Huber G, Loffler J, Richards JG (1994) Increased monoamine oxidase B activity in plaque-associated astro-cytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience 62, 15-30. (Pubitemid 24287342)
35. Sayre LM, Perry G, Smith MA (2008) Oxidative stress and neurotoxicity. Chem Res Toxicol 21, 172-188. (Pubitemid 351219718)
36. Reinikainen KJ, Soininen H, Riekkinen PJ (1990) Neuro-transmitter changes in Alzheimer's disease: Implications to diagnostics and therapy. J Neurosci Res 27, 576-586.
37. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ (1997) A controlled trial of selegi-line, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 336, 1216-1222. (Pubitemid 27183651)
38. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E (2009) A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 361, 1268-1278.
39. Weinreb O, Amit T, Bar-Am O, Youdim MB (2010) Rasagiline: A novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol 92, 330-344.
40. Weinreb O, Amit T, Bar-Am O, Chillag-Talmor O, Youdim MB (2005) Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: Interaction of Bcl-2 family members with PKC pathway. Ann N Y Acad Sci 1053, 348-355. (Pubitemid 43031115)
41. Bar-Am O, Weinreb O, Amit T, Youdim MB (2005) Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J 19, 1899-1901. (Pubitemid 41598788)
42. Weinreb O, Amit T, Bar-Am O, Youdim MB (2007) Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: New insights and implications for therapy. Ann N Y Acad Sci 1122, 155-168. (Pubitemid 350249546)
43. Zheng H, Weiner LM, Bar-Am O, Epsztejn S, Cabantchik ZI, Warshawsky A, Youdim MB, Fridkin M (2005) Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg Med Chem 13, 773-783. (Pubitemid 40093620)
44. Avramovich-Tirosh Y, Reznichenko L, Mit T, Zheng H, Fridkin M, Weinreb O, Mandel S, Youdim MB (2007) Neu-rorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron-chelating-antioxidants, M-30 and green tea polyphenol, EGCG. Curr Alzheimer Res 4, 403-411. (Pubitemid 47416633)
45. Hegde ML, Bharathi P, Suram A, Venugopal C, Jagannathan R, Poddar P, Srinivas P, Sambamurti K, Rao KJ, Scancar J, Messori L, Zecca L, Zatta P (2009) Challenges associated with metal chelation therapy in Alzheimer's disease. J Alzheimers Dis 17, 457-468.
46. Mechlovich D, Amit T, Mandel SA, Bar-Am O, Bloch K, Vardi P, Youdim MB (2010) The novel multifunctional, iron-chelating drugs M30 and HLA20 protect pancreatic beta-cell lines from oxidative stress damage. J Pharmacol Exp Ther 333, 874-882.
47. Kupershmidt L, Weinreb O, Amit T, Mandel S, Carri MT, Youdim MB (2009) Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J 23, 3766-3779.
48. Zheng H, Gal S, Weiner LM, Bar-Am O, Warshawsky A, Fridkin M, Youdim MB (2005) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: In vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem 95, 68-78. (Pubitemid 41384426)
49. Gal S, Zheng H, Fridkin M, Youdim MB (2005) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J Neurochem 95, 79-88. (Pubitemid 41384427)
50. Gal S, Abassi ZA, Youdim MB (2010) limited potentia-tion of blood pressure in response to oral tyramine by the anti-Parkinson brain selective multifunctional monoamine oxidase-AB inhibitor, M30. Neurotox Res 18, 143-150.
51. Avramovich-Tirosh Y, Amit T, Bar-Am O, Zheng H, Fridkin M, Youdim MB (2007) Therapeutic targets and potential of the novel brain-permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. J Neurochem 100, 490-502. (Pubitemid 46016026)
52. Reznichenko L, Amit T, Zheng H, Avramovich-Tirosh Y, Youdim MB, Weinreb O, Mandel S (2006) Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: Implications for iron chelation in Alzheimer's disease. J Neurochem 97, 527-536.
53. Avramovich-Tirosh Y, Bar-Am O, Amit T, Youdim MB, Weinreb O (2010) Up-regulation of hypoxia-inducible factor (HIF)-1alpha and HIF-target genes in cortical neurons by the novel multifunctional iron chelator anti-Alzheimer drug, M30. Curr Alzheimer Res 7, 300-306.
54. Abdipranoto A, Wu S, Stayte S, Vissel B (2008) The role of neurogenesis in neurodegenerative diseases and its implications for therapeutic development. CNS Neurol Disord Drug Targets 7, 187-210.
55. Kupershmidt L, Weinreb O, Amit T, Mandel S, Bar-Am O, Youdim MB (2011) Novel molecular targets of the neuropro-tective/neurorescue multimodal iron chelating drug M30 in the mouse brain. Neuroscience 189, 345-358.
56. Gal S, Zheng H, Fridkin M, Youdim MB (2010) Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30. Neurotox Res 17, 15-27.
57. Singh AT, Bhattacharyya RS, Radeff JM, Stern PH (2003) Regulation of parathyroid hormone-stimulated phospholipase D in UMR-106 cells by calcium, MAP kinase, and small G proteins. J Bone Miner Res 18, 1453-1460. (Pubitemid 41070799)
58. Correia SC, Moreira PI (2010) Hypoxia-inducible factor 1: A new hope to counteract neurodegeneration? J Neurochem 112, 1-12.
59. Hamrick SE, McQuillen PS, Jiang X, Mu D, Madan A, Fer-riero DM (2005) A role for hypoxia-inducible factor-1alpha in desferoxamine neuroprotection. Neurosci Lett 379, 96-100.
60. Massoud F, Gauthier S (2010) Updateonthe pharmacological treatment of Alzheimer's disease. Curr Neuropharmacol 8, 69-80.
61. Munoz-Torrero D (2008) Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease. Curr Med Chem 15, 2433-2455.
62. Mancini F, Naldi M, Cavrini V, Andrisano V (2007) Multiwell fluorometric and colorimetric microassays for the evaluation of beta-secretase (BACE-1) inhibitors. Anal Bioanal Chem 388, 1175-1183. (Pubitemid 47150038)
63. Kimura M, Akasofu S, Ogura H, Sawada K (2005) Protective effect of donepezil against Abeta (1-40) neurotoxicity in rat septal neurons. Brain Res 1047, 72-84. (Pubitemid 40805032)
64. Kimura M, Komatsu H, Ogura H, Sawada K (2005) Comparison of donepezil and memantine for protective effect against amyloid-beta (1-42) toxicity in rat septal neurons. Neurosci Lett 391, 17-21. (Pubitemid 41642670)
65. Meunier J, Ieni J, Maurice T (2006) The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor. Br J Pharmacol 149, 998-1012. (Pubitemid 44950803)
66. Meunier J, Ieni J, Maurice T (2006) Antiamnesic and neuro-protective effects of donepezil against learning impairments induced in mice by exposure to carbon monoxide gas. J Pharmacol Exp Ther 317, 1307-1319. (Pubitemid 43764137)
67. Marrazzo A, Caraci F, Salinaro ET, Su TP, Copani A, Ron-sisvalle G (2005) Neuroprotective effects of sigma-1 receptor agonists against beta-amyloid-induced toxicity. Neuroreport 16, 1223-1226. (Pubitemid 41058473)
68. Bullock R, Dengiz A (2005) Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years. Int J Clin Pract 59, 817-822. (Pubitemid 43904548)
69. Ito K, Ahadieh S, Corrigan B, French J, Fullerton T, Tens-feldt T (2010) Disease progression meta-analysis model in Alzheimer's disease. Alzheimers Dement 6, 39-53.
70. Inestrosa NC, Alvarez A, Perez CA, Moreno RD, Vicente M, Linker C, Casanueva OI, Soto C, Garrido J (1996) Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: Possible role of the peripheral site of the enzyme. Neuron 16, 881-891. (Pubitemid 26124065)
71. Diamant S, Podoly E, Friedler A, Ligumsky H, Livnah O, Soreq H (2006) Butyrylcholinesterase attenuates amyloid fibril formation in vitro. Proc Natl Acad Sci USA 103, 8628-8633. (Pubitemid 43878071)
72. Piazzi L, Rampa A, Bisi A, Gobbi S, Belluti F, Cavalli A, Bartolini M, Andrisano V, Valenti P, Recana-tini M (2003) 3-(4-[[Benzyl (methyl) amino]methyl]phenyl)-6, 7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: A dual function lead for Alzheimer's disease therapy. J Med Chem 46, 2279-2282. (Pubitemid 36637912)
73. Belluti F, Rampa A, Piazzi L, Bisi A, Gobbi S, Bar-tolini M, Andrisano V, Cavalli A, Recanatini M, Valenti P (2005) Cholinesterase inhibitors: Xanthostigmine derivatives blocking the acetylcholinesterase-induced beta-amyloid aggregation. J Med Chem 48, 4444-4456. (Pubitemid 40884946)
74. Zheng H, Youdim MB, Fridkin M (2009) Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer's therapy. J Med Chem 52, 4095-4098.
75. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46, 3-26. (Pubitemid 33653411)
76. Shachar DB, Kahana N, Kampel V, Warshawsky A, Youdim MB (2004) Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology 46, 254-263. (Pubitemid 37532833)
77. Jann MW (2000) Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy 20, 1-12. (Pubitemid 30036098)
78. Zheng H, Fridkin M, Youdim MB (2010) Selective acetyl-cholinesterase inhibitor activated by acetylcholinesterase releases an active chelator with neurorescuing and Anti-Amyloid activities. ACS Chem Neurosci 1, 737-746.
79. Winblad B, Grossberg G, Frolich L, Farlow M, Zechner S, Nagel J, Lane R (2007) IDEAL: A 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 69, S14-S22. (Pubitemid 47205655)
80. Schneider LS, Olin JT, Pawluczyk S (1993) A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease. Am J Psychiatry 150, 321-323. (Pubitemid 23046522)
81. Weinreb O, Amit T, Bar-Am O, Youdim MB (2011) A novel anti-Alzheimer's disease drug, ladostigil neuropro-tective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor. Int Rev Neurobiol 100, 191-215.
82. Yogev-Falach M, Bar-Am O, Amit T, Weinreb O, Youdim MB (2006) A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing. FASEB J 20, 2177-2179.
83. Zheng H, Youdim MB, Fridkin M (2010) Site-activated chela-tors targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy. ACS Chem Biol 5, 603-610.
84. Gozes I, Divinsky I, Pilzer I, Fridkin M, Brenneman DE, Spier AD (2003) From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: A view of neuroprotection and cell division. J Mol Neurosci 20, 315-322. (Pubitemid 38146988)
85. Gozes I, Giladi E, Pinhasov A, Bardea A, Brenneman DE (2000) Activity-dependent neurotrophic factor: Intranasal administration of femtomolar-acting peptides improve performance in a water maze. J Pharmacol Exp Ther 293, 1091-1098. (Pubitemid 30417880)
86. Brenneman DE, Spong CY, Hauser JM, Abebe D, Pinhasov A, Golian T, Gozes I (2004) Protective peptides that are orally active and mechanistically nonchiral. J Pharmacol Exp Ther 309, 1190-1197. (Pubitemid 38669709)
87. Wilkemeyer MF, Chen SY, Menkari CE, Brenneman DE, Sulik KK, Charness ME (2003) Differential effects of ethanol antagonism and neuroprotection in peptide fragment NAPVSIPQ prevention of ethanol-induced developmental toxicity. Proc Natl Acad Sci USA 100, 8543-8548. (Pubitemid 36849603)
88. Gozes I (2011) NAP (davunetide) provides functional and structural neuroprotection. Curr Pharm Des 17, 1040-1044.
89. Soto C (1999) Plaque busters: Strategies to inhibit amyloid formation in Alzheimer's disease. Mol Med Today 5, 343-350. (Pubitemid 29364561)
90. Kayyali R, Pannala AS, Khodr H, Hider RC (1998) Comparative radical scavenging ability of bidentate iron (III) chelators. Biochem Pharmacol 55, 1327-1332. (Pubitemid 28206723)
91. Kaur D, Yantiri F, Rajagopalan S, Kumar J, Mo JQ, Boon-plueangR, Viswanath V, Jacobs R, Yang L, Beal MF, DiMonte D, Volitaskis I, Ellerby L, Cherny RA, Bush AI, Andersen JK (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: A novel therapy for Parkinson's disease. Neuron 37, 899-909. (Pubitemid 36398297)
92. Blat D, Weiner L, Youdim MB, Fridkin M (2008) A Novel iron-chelating derivative of the neuroprotective peptide NAPVSIPQ shows superior antioxidant and antineurodegen-erative capabilities. J Med Chem 51, 126-134.
93. Zheng H, Blat D, Fridkin M (2006) Novel neuroprotec-tive neurotrophic NAP analogs targeting metal toxicity and oxidative stress: Potential candidates for the control of neu-rodegenerative diseases. J Neural Transm Suppl 163-172. (Pubitemid 351412118)
94. Gozes I, Bardea A, Bechar M, Pearl O, Reshef A, Zamostiano R, Davidson A, Rubinraut S, Giladi E, Fridkin M, Brenneman DE (1997) Neuropeptides and neuronal survival: Neuropro-tective strategy for Alzheimer's disease. Ann N Y Acad Sci 814, 161-166. (Pubitemid 27246353)
95. Perez LR, Franz KJ (2010) Minding metals: Tailoring multifunctional chelating agents for neurodegenerative disease. Dalton Trans 39, 2177-2187.